Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT05545007 Recruiting - Clinical trials for Brain Metastases, Adult

Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases

SUPPORT
Start date: January 31, 2023
Phase: N/A
Study type: Interventional

This is a phase III randomized trial with the aim to compare preoperative HSRS to postoperative HSRS in patients with large at least one BMs from solid tumors suitable for surgical resection.

NCT ID: NCT05544253 Recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC

Start date: October 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Hepatocellular carcinoma (HCC) is featured by the spontaneously rupture when suffering severe cirrhosis and intratumoral overpressure. It is a fatal complication with an acute mortality. Importantly, it is served as an independent risk factor for peritoneal metastasis (PM) of HCC with poor prognosis. The systematic agents effective to extrahepatic lesions confers modest efficacy towards PM. HIPEC, as a novel strategy, has been proved by overwhelming studies that it is effective to peritoneal malignant tumors. However, there is absence of prospective study of HIPEC efficacy towards HCC.

NCT ID: NCT05544240 Recruiting - Cancer Clinical Trials

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

Start date: February 1, 2023
Phase: Phase 1
Study type: Interventional

SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

NCT ID: NCT05543928 Recruiting - Clinical trials for Vitamin d Deficiency

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

Start date: January 31, 2023
Phase: Phase 3
Study type: Interventional

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.

NCT ID: NCT05539300 Recruiting - Prostate Cancer Clinical Trials

PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide

PET-MaN-enza
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

PSMA-PET/CT response measurements after LHRH agonist and upfront enzalutamide therapy in men diagnosed with de novo metastasized hormonal sensitive prostate cancer.

NCT ID: NCT05535413 Recruiting - Brain Metastases Clinical Trials

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, multicenter, open-labeled clinical study of UTD1 combined with Capecitabine in metastatic HER2-negative breast cancaner patients with brain metastases. This study aims to evaluate the efficacy and safety of UDT1 combined with capecitabine in metastatic HER2-negative breast cancer patients with brain metastases.

NCT ID: NCT05534321 Recruiting - Spine Metastases Clinical Trials

Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease

PROMISSeD
Start date: August 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Early palliative care has been shown to improve the quality of life and even survival for patients with metastatic cancer. More and more supportive oncology teams in cancer centers now advocate for early integration of radiation therapy (RT) in a patient's palliative management course. While multiple randomized studies have evaluated the efficacy of different RT regimens in the treatment of symptomatic bone lesions, few studies have examined the impact of early, upfront RT for asymptomatic or minimally symptomatic (non- opioid dependent) spine metastases and its efficacy in preventing skeletal-related events (SREs). Since the pathophysiology of spinal metastatic disease is distinct from other bony metastatic disease, the proposed trial seeks to understand whether it is beneficial to patients with minimally symptomatic disease to undergo upfront RT to reduce the risks of SREs and their sequelae, including hospitalizations.

NCT ID: NCT05524064 Recruiting - Clinical trials for Bone Metastases in the Thorax

FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax

FAST-02
Start date: March 8, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess toxicities of FLASH radiotherapy treatment and pain relief in subjects with painful thoracic bone metastases. FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.

NCT ID: NCT05518526 Recruiting - Soft Tissue Sarcoma Clinical Trials

Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases

ANNA-SARC
Start date: August 23, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multi-centre, open-label, single-arm, 3+3 Phase 1b/ and Phase II. Phase 1b is aimed to determine the maximum-tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) based on safety reporting. The RP2D is a multifactorial endpoint that considers toxicity as well as additional determinants (e.g. efficacy, pharmacodynamics) to define the optimal Phase 2 dose. Phase 2 will explore the efficacy of L-Annamycin at RP2D for treating soft tissue sarcomas (STS) subjects with lung metastases, for which chemotherapy is considered appropriate.

NCT ID: NCT05518253 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start date: May 30, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.